Traws Pharma
TRAW
30 hedge funds and large institutions have $2.36M invested in Traws Pharma in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
0% more funds holding
Funds holding: 30 → 30 (0)
0.03% less ownership
Funds ownership: 0.38% → 0.34% (-0.03%)
35% less capital invested
Capital invested by funds: $3.61M → $2.36M (-$1.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$80.3K |
| 2 |
Millennium Management
New York
|
+$50.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.3K |
| 4 |
SG
StoneX Group
New York
|
+$20.2K |
| 5 |
Jane Street
New York
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$234K |
| 2 |
Two Sigma Investments
New York
|
-$117K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$35K |
| 5 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| – | -$3K | -59 | Closed |
|
27
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$34 | +1 | New |
|
28
Citigroup
New York
| – | +$169 | +5 | New |
|
|
CFN
29
Cordasco Financial Network
Naples,
Florida
| – | +$169 | +5 | New |
|
|
GWS
30
Glassman Wealth Services
Vienna,
Virginia
| – | +$169 | +5 | New |
|
TRAW Hedge Fund Activity: Q2 2022 in Review
30 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2022, worth a combined $2.36M — down 35% from $3.61M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TRAW positions and 6 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $80.3K. The largest seller was Two Sigma Advisers, cutting an estimated $234K.
- 30 institutional investors held Traws Pharma (TRAW) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $2.36M of Traws Pharma stock for Q2 2022, down 35% quarter-over-quarter.
- 8 funds opened new Traws Pharma positions in Q2 2022 and 6 closed out, a net change of +2 holders.
- The largest Traws Pharma buyer in Q2 2022 was Citadel Advisors, an estimated $80.3K added.
- The largest Traws Pharma seller in Q2 2022 was Two Sigma Advisers, an estimated $234K sold.
Based on aggregated 13F filings for Q2 2022.